A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value. Novartis AG ADR's 'price/earnings-to-growth ratio' can be calculated by dividing its P/E ratio by its growth – to give 4.4413.

The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued. That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). In other words, Novartis AG ADR shares trade at around 8x recent earnings. Novartis AG ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a 'trailing price/earnings ratio' of roughly 8x. However, analysts commonly use some key metrics to help gauge the value of a stock. Valuing Novartis AG ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novartis AG ADR's overall performance. Is Novartis AG ADR under- or over-valued? With no account fee, the mobile app is clean and intuitive to use. We chose Wealthsimple for this category because it offers commission-free trading. We chose Interactive Brokers for this category because it offers extensive trading capabilities and access to advanced trading tools to help traders in their investing journey, as well as access to a large number of international stock exchanges. In addition, students can take advantage of special pricing for making trades if they have a CIBC Student Bank account. We chose CIBC Investor's Edge for this category because it offers low and competitive fees, as well as an easy-to-use, user-friendly interface and provides a number of learning resources to help you get acquainted with the platform. We encourage you to compare stock platforms to find one that's best for your particular budget and goals. You can learn more about our methodology here. Lutathera was approved in Europe in September 2017 for treating unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. AAA had sales of EUR 109 million ($126 million) in 2016. AAA also develops, manufactures, and commercializes companion diagnostics for Lutathera (Netspot and SomaKit TOC). Radiopharmaceuticals, such as Lutathera, are medicinal formulations containing radioisotopes, which are used clinically for diagnosis and therapy, according to Novartis. It was approved for treating a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors (GEP-NETs). After binding to the receptor, the drug enters the cell allowing radiation to cause damage to the tumor cells. Lutathera is a radioactive drug that works by binding to a part of a cell called a somatostatin receptor, which may be present on certain tumors, according to information from the FDA. AAA develops, produces, and commercializes molecular nuclear medicines, including Lutathera. Novartis acquired AAA, a Saint-Genis-Pouilly, France-headquartered radiopharmaceutical company, for $3.9-billion in January 2018.

The US Food and Drug Administration (FDA) has approved Lutathera (lutetium Lu 177 dotatate), a radiopharmaceutical for treating certain digestive tract cancers, from Advanced Accelerator Applications (AAA), a subsidiary of Novartis.

Novartis Gets FDA Approval for Cancer Radiopharmaceutical

A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Novartis.Įditor’s Note: This article was updated on a continuous basis for news announced from Wednesday Janudate to Tuesday January 30, 2018.

Netspot novartis